International Advocacy

This month, BIO is leading a delegation of biopharma CEOs to China for meetings with members of the Chinese biotech community and government leaders. The mission illustrates a strong commitment on behalf of the western biotechnology industry to encourage China to strengthen its support for biotech innovation and take steps to enhance greater investment and collaboration with companies in China. The series of meetings between China’s local industry and government leaders and biotech CEOs will lay the foundation for increased cooperation to help biotech flourish in China.

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year’s BIO International Convention.  Created in partnership with BIO, the publication explores the diverse economic regions of the world, highlighting success stories, policy achievements, cutting-edge science and the unique challenges that lie ahead. This year’s report focuses on BRIC (Brazil, Russia, India and China) country efforts to build local biotechnology hubs. 

A new federal recommendation could hinder innovations from biotechnology R&D by limiting gene patents and licenses.

Are biotech drugs really that different from traditional pharmaceuticals.  You bet they are.  Learn why here.

After a few chilly days here in Atlanta, Tuesday brought a beautiful evening for a gathering of public officials atop the Metro Atlanta Chamber of Commerce.

Last night research, industry and politics got together at Dailey's in Atlanta for a little meeting. It was actually a networking reception but let's face it, we were all about ensuring the wheels of biotechnology kept turning in Canada.

Mexico is the fifth richest region in biodiversity in the world with a long tradition of research in biological sciences.

Tracy Krughoff speaks with Fernando Quesada, executive director of the Biotechnology Center of Excellence Corporation, who is organizing Mexico’s participation in the BIO International Convention.

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

The Earth Summit at Rio de Janeiro in 1992 established a vision of "Sustainable Development." Where development historically was based almost entirely on economic calculations, there would now be an environmental component as well.

Letters, Testimony & Comments

June 7 2013
BIO applauds the government of Brazil for taking steps towards developing regulatory requirements to ensure patients suffering from rare diseases have access to treatment.   
June 3 2013
BIO appreciates the opportunity to respond to the Request for Comments issued by the U.S. Trade Representative on objectives to be pursued in the negotiation of a Transatlantic Trade and Investment Partnership (TTIP) agreement. 
March 21 2013
BIO commends the Government of Peru for its endeavor to create a pathway for the approval of biological and biotechnological products. Peru is a growing market for biotechnology products and with the implementation of the US-Peru TPA, it promises to become an even bigger market.
February 22 2013
BIO commends the government of Colombia for taking steps towards developing regulatory requirements for the registry of medicines of biological origin. Many elements of the third draft appear to have addressed BIO's previous comments with respect to clarity of structure and definitions of terms, as well as expectations for data requirements.   
February 8 2013
Biotechnology companies provide unique benefits to the United States and the world. In the health care sector alone, the industry has developed and commercialized more than 300 biotechnology drugs and diagnostics and there are over 400 products in the pipeline.

Press Releases

April 8 2013
Strong Intellectual Property Protection Is Vital For The Life Sciences Industry.
July 23 2012
Groups issue booklet to help biotechnology and pharmaceutical companies identify pipeline medicines with doping potential.
June 6 2012
The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."
April 5 2012
Centric Health Resources and the National Organization for Rare Disorders (NORD), Co-organizersAlnylam Pharmaceuticals, Genzyme, a Sanofi Company and Millennium: The Takeda Oncology Company, Co-sponsors
October 5 2011
BIO welcomed the transmission of the Korea-U.S. Free Trade Agreement (KORUS FTA) by President Obama to the Congress earlier this week.